New Haven, Conn., March 18, 2019 – Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the American Association for Cancer Research (AACR) Annual Meeting 2019, being held March 29 – April 3 in Atlanta, Georgia. At the meeting, the Company will unveil the FDA-approved poly ADP-ribose polymerase (PARP) inhibitor conjugated in CBX-11.
CBX-11 combines Cybrexa’s proprietary alphalex™ tumor targeting technology with an already-approved oral small molecule PARP inhibitor. CBX-11 will be evaluated in combination with DNA damaging chemotherapy for the treatment of patients with solid tumors that lack homologous recombination deficiency (HRD). The company remains on track to submit its Investigational New Drug (IND) application for CBX-11 by the fourth quarter of 2019, with a Phase 1 clinical trial evaluating CBX-11 in combination with chemotherapy anticipated to begin in the first quarter of 2020.
Details for the poster presentation are as follows:
Targeting solid tumor acidic microenvironment with an alphalex PARP inhibitor
Permanent Abstract # 2981 / Poster #3
Session: Diagnostics, Biomarkers, and the Tumor Microenvironment
Date and Time: Tuesday, April 2; 8:00 am – 12:00 pm EST
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 11
Presenting Author: Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa
“This marks the first set of preclinical data supporting our lead candidate CBX-11, which we formally announced at the beginning of the year,” said Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa. “Our alphalex™ tumor targeting technology represents a novel approach to enable the synergistic efficacy of a PARP inhibitor and chemotherapy administered at full dose. We are excited to share these compelling data and take the opportunity to unveil the composition of CBX-11, especially given the current development landscape and high profile of PARP inhibitors.”
About the alphalex™ Technology Platform
The Cybrexa alphalex™ technology platform enables the delivery of small molecules across the cell membrane under low pH conditions, which is a universal feature of cancer cells. As a result, alphalex™ technology – which consists of a novel peptide, linker and small molecule anti-cancer agent – allows for antigen-independent, intracellular delivery of small molecule anti-cancer agents directly into the tumor cell. View a video of the mechanism of action of the technology at https://www.cybrexa.com/our-technology.
About Cybrexa
Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells. The Company’s lead candidate, CBX-11, an alphalex™-PARP inhibitor combination, is in preclinical development with advancing plans to initiate clinical development by 1Q 2020. Cybrexa was founded by physician-scientists, and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com.
Contacts
Media Relations